Eli Lilly agreed on 20 April to acquire Kelonia Therapeutics, a Boston clinical-stage biotech, for $3.25bn in cash upfront and up to $7bn including milestones.
Why Eli Lilly and Company is buying Kelonia Therapeutics, Inc.
Kelonia's in vivo gene placement system uses engineered lentiviral-based particles to enter T-cells inside the body, so patients generate their own CAR-T cells. Lilly said the approach could remove the manufacturing, safety and access barriers that mean only a fraction of eligible patients receive autologous CAR-T therapy. Lead programme KLN-1010, a one-time intravenous anti-BCMA therapy for multiple myeloma, presented early data at the 2025 ASH annual meeting plenary session.
“The early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia's platform.”
Deal terms and financing
Kelonia shareholders receive up to $7.00bn in cash, made up of $3.25bn upfront and subsequent payments tied to clinical, regulatory and commercial milestones.
Regulatory approvals and timing
The deal was subject to customary conditions, including regulatory approvals. Lilly's quarterly report for the period to 30 June 2026 records 25 June 2026 as the acquisition date, with $3.09bn of cash consideration net of cash acquired and up to $3.75bn of contingent consideration.
Market context
Kelonia, backed by Venrock, had 62 employees, most of them in Boston, according to The Boston Globe. Lilly closed its acquisition of sleep-disorder drug developer Centessa Pharmaceuticals a day earlier, on 24 June, and has also bought Ventyx, Orna and Ajax in 2026.
